Table 2.
Most frequent treatment-emergent adverse events reported in at least 4 patients for up to 240 weeks of eteplirsen treatment in combined studies 201 and 202.

Most frequent treatment-emergent adverse events reported in at least 4 patients for up to 240 weeks of eteplirsen treatment in combined studies 201 and 202.
